KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) EBT (2016 - 2025)

Historic EBT for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to -$30.0 million.

  • NovoCure's EBT fell 3908.73% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$150.5 million, marking a year-over-year decrease of 3145.43%. This contributed to the annual value of -$131.2 million for FY2024, which is 3159.38% up from last year.
  • NovoCure's EBT amounted to -$30.0 million in Q3 2025, which was down 3908.73% from -$35.0 million recorded in Q2 2025.
  • In the past 5 years, NovoCure's EBT registered a high of -$2.5 million during Q1 2022, and its lowest value of -$55.2 million during Q4 2024.
  • Moreover, its 5-year median value for EBT was -$30.0 million (2025), whereas its average is -$29.1 million.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 193101.39% in 2023, then surged by 5783.43% in 2024.
  • Over the past 5 years, NovoCure's EBT (Quarter) stood at -$25.6 million in 2021, then dropped by 27.31% to -$32.6 million in 2022, then fell by 18.35% to -$38.5 million in 2023, then crashed by 43.27% to -$55.2 million in 2024, then surged by 45.62% to -$30.0 million in 2025.
  • Its last three reported values are -$30.0 million in Q3 2025, -$35.0 million for Q2 2025, and -$30.3 million during Q1 2025.